|Articles|March 26, 2007

ACT July 2007 Ad Performance Study

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© photon_photo - © photon_photo - stock.adobe.com

Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology

ByPeter Schüler, MD,Jack L. Martin, MD, FACC

August 28th 2026

How Urgent Is the Site Payment Problem, and Is the Industry Finally Taking It Seriously?

ByPatrick Mizer,Andy Studna, Senior Editor

August 28th 2026

ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise

ByAndy Studna, Senior Editor

August 28th 2026

What Sponsors Stand to Lose If Site Payment Infrastructure Doesn't Improve

ByPatrick Mizer,Andy Studna, Senior Editor

August 27th 2026

Generative AI is moving faster than any technology shift in history—and sponsors and CROs that treat a powerful model as a strategy, rather than a governed, validated workflow, are gambling with patient safety and regulatory standing.

AI Is Moving Faster Than Any Technology Before It

ByPhilip Raeth

August 27th 2026

ACT July 2007 Ad Performance Study

Related Content

Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology

How Urgent Is the Site Payment Problem, and Is the Industry Finally Taking It Seriously?

ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise

What Sponsors Stand to Lose If Site Payment Infrastructure Doesn't Improve

AI Is Moving Faster Than Any Technology Before It

Trending on Applied Clinical Trials Online

Where AI Is Delivering Real Value in Clinical Trial Payments Right Now

ACT Brief: AI in Invoice Processing, Botanical Medicines and FDA Pathways, and Connected Trial Finance Systems

How Urgent Is the Site Payment Problem, and Is the Industry Finally Taking It Seriously?

Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology

ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise